RT Journal Article
SR Electronic
T1 Seroconversion rates following COVID-19 vaccination amongst patients with malignant disease- the impact of diagnosis and cancer-directed therapies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.07.21256824
DO 10.1101/2021.05.07.21256824
A1 Thakkar, Astha
A1 Lugo, Jesus Gonzalez
A1 Goradia, Niyati
A1 Gali, Radhika
A1 Shapiro, Lauren C.
A1 Pradhan, Kith
A1 Rahman, Shafia
A1 Kim, So Yeon
A1 Ko, Brian
A1 Sica, R. Alejandro
A1 Kornblum, Noah
A1 Bachier-Rodriguez, Lizamarie
A1 McCort, Margaret
A1 Goel, Sanjay
A1 Perez-Soler, Roman
A1 Packer, Stuart
A1 Sparano, Joseph
A1 Gartrell, Benjamin
A1 Makower, Della
A1 Goldstein, Yitz D
A1 Wolgast, Lucia
A1 Verma, Amit
A1 Halmos, Balazs
YR 2021
UL http://medrxiv.org/content/early/2021/05/14/2021.05.07.21256824.abstract
AB As COVID-19 has been shown to adversely affect patients with cancer, prophylactic strategies are critically needed. We determined the immunogenicity of COVID-19 vaccination in a cohort of cancer patients that had received full dosing with one of the FDA-approved COVID-19 vaccines. 201 oncology patients underwent anti-spike protein SARS-CoV-2 IgG testing post vaccination and demonstrated a high rate of seroconversion (94%) overall. When compared to solid tumors (98%), a significantly lower rate of seroconversion was observed in patients with hematological malignancies (85%), particularly recipients of anti-CD20 therapies (70%) and stem cell transplantation (74%). Patients receiving immune checkpoint inhibitor therapy (97%) or hormonal therapies (100%) demonstrated high seroconversion post-vaccination. Patients with prior COVID-19 infection demonstrated higher anti-spike IgG titers post-vaccination. Relatively lower IgG titers were noted following vaccination with the adenoviral when compared to the mRNA-based vaccines. These data demonstrate generally high immunogenicity of COVID-19 vaccination in oncology patients and identify vulnerable cohorts that need novel vaccination or passive immunization strategies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge Cancer Center grant P30 CA013330 and NCORP grant 2UG1CA189859-06 in providing funding for this project. This work was supported partly by the Jane A. and Myles P. Dempsey fund. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Montefiore-Einstein Institutional Review BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available with the corresponding author upon request